secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0000950170-22-022604
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent Genetics Q3 core revenue up 110% to $56M; acquires Fulgent Pharma for ~$100M
--------------------------------------------------------------------------------

- Q3 revenue $105.7M (down 54% YoY due to COVID decline); GAAP EPS $0.06, non-GAAP EPS $0.32.
- Core revenue (ex-COVID) grew 110% YoY to $56.0M; adjusted EBITDA $19.7M.
- Acquired Fulgent Pharma for ~$100M (cash + stock), a clinical-stage therapeutics company with nano-drug delivery platform.
- Lead candidate FID-007 for head & neck cancer; combined company offers vertically integrated oncology precision medicine.
- Cash, cash equivalents and investments of $918.0M as of Sep 30, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000095017022022604/0000950170-22-022604-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000095017022022604/flgt-20221107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-022604

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer